ES2149780T3 - Acidos salicilicos sustituidos para el tratamiento de enfermedades autoinmunes. - Google Patents

Acidos salicilicos sustituidos para el tratamiento de enfermedades autoinmunes.

Info

Publication number
ES2149780T3
ES2149780T3 ES92924067T ES92924067T ES2149780T3 ES 2149780 T3 ES2149780 T3 ES 2149780T3 ES 92924067 T ES92924067 T ES 92924067T ES 92924067 T ES92924067 T ES 92924067T ES 2149780 T3 ES2149780 T3 ES 2149780T3
Authority
ES
Spain
Prior art keywords
compound
autoimmune diseases
salicilic
acids
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92924067T
Other languages
English (en)
Inventor
Karl Hubert Agback
Leif Ahrgren
Thomas Berglindh
Martin Haraldsson
Lars-Inge Olsson
Goran Smedegard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of ES2149780T3 publication Critical patent/ES2149780T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Abstract

UN COMPUESTO DE LA FORMULA HET-NR-SO2-PH2-A-PH1 (COOH)(OH) Y FORMA TAUTONICA, SALES, SOLVATOS, ESTERES DE ALQUILO C1-6 Y COMPOSICIONES FARMACEUTICAS DEL COMPUESTO. PH1 Y PH2 SON ANILLOS BENCENOS SIEMPRE QUE CARBOXI E HIDROXI SEAN ORTO UNO A UNO. HET COMPRENDE UN ANILLO HETEROCICLICO OPCIONALMENTE SUSTITUIDO QUE COMPRENDE ENLACES DOBLES CONJUGADOS Y SE ENLAZA NITROGENO EN NR. EL COMPUESTO SE CARACTERIZA EN QUE A ES UN PUENTE QUE ES ESTABLE CONTRA LA REDUCCION YA QUE NO ES AZO, Y EN QUE R ES HIDROGENO O ALQUILO INFERIOR. LA INVENCION TAMBIEN COMPRENDE LA PREPARACION DEL COMPUESTO Y SU USO COMO UN MEDICAMENTO, PARTICULARMENTE PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES.
ES92924067T 1991-11-18 1992-11-04 Acidos salicilicos sustituidos para el tratamiento de enfermedades autoinmunes. Expired - Lifetime ES2149780T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror

Publications (1)

Publication Number Publication Date
ES2149780T3 true ES2149780T3 (es) 2000-11-16

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92924067T Expired - Lifetime ES2149780T3 (es) 1991-11-18 1992-11-04 Acidos salicilicos sustituidos para el tratamiento de enfermedades autoinmunes.

Country Status (29)

Country Link
US (3) US5302718A (es)
EP (1) EP0613468B1 (es)
JP (1) JP3259915B2 (es)
KR (1) KR100253748B1 (es)
AT (1) ATE194597T1 (es)
AU (1) AU668528B2 (es)
CA (1) CA2123697C (es)
DE (1) DE69231252T2 (es)
DK (1) DK0613468T3 (es)
EE (1) EE03026B1 (es)
ES (1) ES2149780T3 (es)
FI (1) FI106857B (es)
GR (1) GR3034585T3 (es)
HU (2) HU221476B (es)
IL (1) IL103665A (es)
LT (1) LT3182B (es)
LV (1) LV10246B (es)
MX (1) MX9206647A (es)
MY (1) MY130169A (es)
NO (1) NO300805B1 (es)
NZ (1) NZ244998A (es)
PT (1) PT101068B (es)
RU (1) RU2124501C1 (es)
SE (1) SE9103397D0 (es)
SK (1) SK282080B6 (es)
TW (1) TW304944B (es)
UA (1) UA42869C2 (es)
WO (1) WO1993010094A1 (es)
ZA (1) ZA928864B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
EP0788353A1 (en) 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Ppar gamma antagonists for treating obesity
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
SG87052A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co Pinacol ester intermediates useful for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 ４−フルオロサリチル酸類
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
AU4676999A (en) 1998-06-12 1999-12-30 Ligand Pharmaceuticals, Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators
MXPA01009362A (es) 1999-03-19 2002-06-04 Squibb Bristol Myers Co Metodos para la preparacion de bifenil isoxazol sulfonamidas.
ES2307528T3 (es) 1999-09-04 2008-12-01 Astrazeneca Ab Amidas como inhibidores para la piruvato deshidrogenasa.
EP1214295B1 (en) 1999-09-04 2006-11-02 AstraZeneca AB Hydroxyacetamidobenzenesulphonamide derivatives
BR0013694A (pt) 1999-09-04 2002-05-21 Astrazeneca Ab Composto, processo para a preparação de um composto, composição farmacêutica, e, uso de um composto
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
AU2001254559A1 (en) * 2000-04-28 2001-11-12 The University Of British Columbia Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
EP1696915A1 (en) * 2003-12-19 2006-09-06 Pfizer, Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
CA2643963A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
CN102076660B (zh) * 2008-06-23 2014-01-08 安斯泰来制药有限公司 磺胺化合物或其盐
EP2677865A4 (en) * 2011-02-23 2015-04-22 Icahn School Med Mount Sinai BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION
HUE050317T2 (hu) 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
CN108602775B (zh) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) * 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Also Published As

Publication number Publication date
NZ244998A (en) 1995-09-26
TW304944B (es) 1997-05-11
CA2123697A1 (en) 1993-05-27
IL103665A0 (en) 1993-04-04
FI942289A0 (fi) 1994-05-17
EE03026B1 (et) 1997-08-15
FI942289A (fi) 1994-05-17
PT101068A (pt) 1994-02-28
SK282080B6 (sk) 2001-10-08
HU9401391D0 (en) 1994-08-29
JPH07501330A (ja) 1995-02-09
MY130169A (en) 2007-06-29
SK54794A3 (en) 1995-02-08
LV10246B (en) 1995-04-20
RU2124501C1 (ru) 1999-01-10
DK0613468T3 (da) 2000-10-23
ZA928864B (en) 1993-05-13
NO300805B1 (no) 1997-07-28
ATE194597T1 (de) 2000-07-15
IL103665A (en) 1997-08-14
US5302718A (en) 1994-04-12
DE69231252T2 (de) 2001-03-01
HU211163A9 (en) 1995-10-30
SE9103397D0 (sv) 1991-11-18
HUT69723A (en) 1995-09-28
MX9206647A (es) 1993-05-01
PT101068B (pt) 1999-08-31
US5403930A (en) 1995-04-04
GR3034585T3 (en) 2001-01-31
EP0613468B1 (en) 2000-07-12
LT3182B (en) 1995-03-27
AU668528B2 (en) 1996-05-09
CA2123697C (en) 2003-12-09
LV10246A (lv) 1994-10-20
NO941799L (es) 1994-06-22
UA42869C2 (uk) 2001-11-15
AU2958992A (en) 1993-06-15
KR100253748B1 (ko) 2000-05-01
HU221476B (en) 2002-10-28
LTIP229A (en) 1994-09-25
US5556855A (en) 1996-09-17
DE69231252D1 (de) 2000-08-17
NO941799D0 (no) 1994-05-13
EP0613468A1 (en) 1994-09-07
FI106857B (fi) 2001-04-30
JP3259915B2 (ja) 2002-02-25
WO1993010094A1 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
ES2149780T3 (es) Acidos salicilicos sustituidos para el tratamiento de enfermedades autoinmunes.
RU94028109A (ru) Новые замещенные салициловые кислоты, способ их получения
PE58699A1 (es) Derivados de acido arilsulfonil hidroxamico
ATE151418T1 (de) Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
FI940414A (fi) Kinoliini- tai kinatsoliinijohdannaiset, niiden valmistus ja käyttö
ATE432262T1 (de) Pyrazolphenylderivate als ppar-aktivatoren
GT200500214A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon
DK0720598T3 (da) Phenoxyphenylcyclopentenyl-hydroxyurinstoffer
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
MX2020008230A (es) Derivados de ester butanoico sustituido con bisfenilo como inhibidores de nep.
NO305799B1 (no) Nye kinolinderivater, farmas°ytiske preparater inneholdende slike derivater, deres anvendelse samt mellomprodukter
ATE378339T1 (de) Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2
PE20230247A1 (es) Inhibidores de ras
PL431613A1 (pl) Związek do zastosowania jako lek, inhibitor kinazy PERK oraz jego zastosowanie do zapobiegania i leczenia chorób neurodegeneracyjnych zależnych od stresu retikulum endoplazmatycznego
ATE361307T1 (de) Neue arzneimittel
TH13794EX (th) ซับสทิทิวเทดซาลิไซลิคแอซิดชนิดใหม่

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 613468

Country of ref document: ES